{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:12:00Z","timestamp":1777961520221,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"CSIR, India","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11878-9","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:35:42Z","timestamp":1777959342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncogenic MAGEA4 directs neuroendocrine differentiation and survival in prostate cancer cells through the SIRT1\/Acetyl-p53\/BCL-2 axis"],"prefix":"10.1007","volume":"53","author":[{"given":"Maresha","family":"Ramakrishna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teja","family":"Nallavolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Ummanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"11878_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"11878_CR2","doi-asserted-by":"publisher","first-page":"102719","DOI":"10.1016\/J.CANEP.2024.102719","volume":"94","author":"V Kumar","year":"2025","unstructured":"Kumar V, Zahiruddin QS, Jena D et al (2025) Understanding current trends and incidence projections of prostate cancer in India: A comprehensive analysis of national and regional data from the global burden of disease study (1990 \u2013\u20092021). Cancer Epidemiol 94:102719. https:\/\/doi.org\/10.1016\/J.CANEP.2024.102719","journal-title":"Cancer Epidemiol"},{"key":"11878_CR3","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI et al (2019) The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res 25:6916\u20136924","journal-title":"Clin Cancer Res"},{"key":"11878_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/NRC4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer. Nat Rev Cancer 15:701. https:\/\/doi.org\/10.1038\/NRC4016","journal-title":"Nat Rev Cancer"},{"key":"11878_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMOA1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med 371:424. https:\/\/doi.org\/10.1056\/NEJMOA1405095","journal-title":"N Engl J Med"},{"key":"11878_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005","journal-title":"N Engl J Med"},{"key":"11878_CR7","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1530\/ERC-11-0141","volume":"18","author":"SM Dehm","year":"2011","unstructured":"Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183\u2013R196","journal-title":"Endocr Relat Cancer"},{"key":"11878_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/J.CELL.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG et al (2018) Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 174:758\u2013769e9. https:\/\/doi.org\/10.1016\/J.CELL.2018.06.039","journal-title":"Cell"},{"key":"11878_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/J.CELL.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R et al (2013) Glucocorticoid Receptor Confers Resistance to Anti-Androgens by Bypassing Androgen Receptor Blockade. Cell 155:1309. https:\/\/doi.org\/10.1016\/J.CELL.2013.11.012","journal-title":"Cell"},{"key":"11878_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/S11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H (2021) Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep 23:15. https:\/\/doi.org\/10.1007\/S11912-020-01003-9","journal-title":"Curr Oncol Rep"},{"key":"11878_CR11","doi-asserted-by":"publisher","first-page":"119085","DOI":"10.1016\/j.bbamcr.2021.119085","volume":"1868","author":"S Natani","year":"2021","unstructured":"Natani S, Dhople VM, Parveen A et al (2021) AMPK\/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells. Biochim et Biophys Acta (BBA)-Molecular Cell Res 1868:119085","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Cell Res"},{"key":"11878_CR12","doi-asserted-by":"publisher","first-page":"110240","DOI":"10.1016\/j.cellsig.2021.110240","volume":"91","author":"S Natani","year":"2022","unstructured":"Natani S, Sruthi KK, Asha SM et al (2022) Activation of TGF-\u03b2-SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK. Cell Signal 91:110240","journal-title":"Cell Signal"},{"key":"11878_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jnr.10160","volume":"67","author":"PA Barker","year":"2002","unstructured":"Barker PA, Salehi A (2002) The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67:705\u2013712","journal-title":"J Neurosci Res"},{"key":"11878_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/NRC1669","volume":"5","author":"AJG Simpson","year":"2005","unstructured":"Simpson AJG, Caballero OL, Jungbluth A et al (2005) Cancer\/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615\u2013625. https:\/\/doi.org\/10.1038\/NRC1669","journal-title":"Nat Rev Cancer"},{"key":"11878_CR15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/J.JMB.2017.03.005","volume":"429","author":"AK Lee","year":"2017","unstructured":"Lee AK, Potts PR (2017) A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. J Mol Biol 429:1114\u20131142. https:\/\/doi.org\/10.1016\/J.JMB.2017.03.005","journal-title":"J Mol Biol"},{"issue":"11","key":"11878_CR16","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/BLOOD.V95.11.3530","volume":"95","author":"H Van Chambost","year":"2000","unstructured":"ChambostH, Van Baren N, Brasseur F, Godelaine D et al (2000) Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood, J Am Soc Hematol 95(11):3530-3. https:\/\/doi.org\/10.1182\/BLOOD.V95.11.3530","journal-title":"Blood, J Am Soc Hematol"},{"issue":"15","key":"11878_CR17","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.3390\/CANCERS15153887","volume":"15","author":"L Landuzzi","year":"2023","unstructured":"Landuzzi L, Manara MC, Pazzaglia L et al (2023) Innovative breakthroughs for the treatment of advanced and metastatic synovial sarcoma. Cancers 15(15):3887. https:\/\/doi.org\/10.3390\/CANCERS15153887","journal-title":"Cancers"},{"key":"11878_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/S10020-025-01079-8","author":"W Zhu","year":"2025","unstructured":"Zhu W, Yi Q, Chen Z et al (2025) Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy. Mol Med. https:\/\/doi.org\/10.1186\/S10020-025-01079-8. 31:","journal-title":"Mol Med"},{"key":"11878_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/15548627.2015.1034420","volume":"11","author":"CT Pineda","year":"2015","unstructured":"Pineda CT, Potts PR (2015) Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. Autophagy 11:844. https:\/\/doi.org\/10.1080\/15548627.2015.1034420","journal-title":"Autophagy"},{"key":"11878_CR20","doi-asserted-by":"publisher","first-page":"S681","DOI":"10.1016\/j.annonc.2024.08.1060","volume":"35","author":"M Wermke","year":"2024","unstructured":"Wermke M, Ochsenreither S, Chatterjee M et al (2024) 1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4\/8-directed half-life extended TCR bispecific, in phase I dose escalation. Ann Oncol 35:S681\u2013S682","journal-title":"Ann Oncol"},{"key":"11878_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1083\/jcb.200304021","volume":"162","author":"JS Da Silva","year":"2003","unstructured":"Da Silva JS, Medina M, Zuliani C et al (2003) RhoA\/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 162:1267\u20131279. https:\/\/doi.org\/10.1083\/jcb.200304021","journal-title":"J Cell Biol"},{"key":"11878_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/NRUROL.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A (2018) Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol 15:271\u2013286. https:\/\/doi.org\/10.1038\/NRUROL.2018.22","journal-title":"Nat Rev Urol"},{"key":"11878_CR23","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.18632\/ONCOTARGET.23111","volume":"9","author":"L Ruan","year":"2017","unstructured":"Ruan L, Wang L, Wang X et al (2017) SIRT1 contributes to neuroendocrine differentiation of prostate cancer. Oncotarget 9:2002\u20132016. https:\/\/doi.org\/10.18632\/ONCOTARGET.23111","journal-title":"Oncotarget"},{"key":"11878_CR24","doi-asserted-by":"publisher","unstructured":"Hu CD, Choo R, Huang J (2015) Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 5. https:\/\/doi.org\/10.3389\/FONC.2015.00090","DOI":"10.3389\/FONC.2015.00090"},{"key":"11878_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0002-9440(10)65277-7","volume":"154","author":"RV Lloyd","year":"1999","unstructured":"Lloyd RV, Erickson LA, Jin L et al (1999) p27(kip1): A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313\u2013323. https:\/\/doi.org\/10.1016\/S0002-9440(10)65277-7","journal-title":"Am J Pathol"},{"key":"11878_CR26","doi-asserted-by":"publisher","unstructured":"Montalto FI, De Amicis F (2020) Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells 9. https:\/\/doi.org\/10.3390\/CELLS9122648","DOI":"10.3390\/CELLS9122648"},{"key":"11878_CR27","doi-asserted-by":"publisher","first-page":"e179998","DOI":"10.1172\/JCI179998","volume":"134","author":"D Westaby","year":"2024","unstructured":"Westaby D, Jim\u00e9nez-Vacas JM, Figueiredo I et al (2024) BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. J Clin Invest 134:e179998","journal-title":"J Clin Invest"},{"key":"11878_CR28","doi-asserted-by":"publisher","unstructured":"Dong B, Miao J, Wang Y et al (2020) Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun Biol 3. https:\/\/doi.org\/10.1038\/S42003-020-01476-1","DOI":"10.1038\/S42003-020-01476-1"},{"key":"11878_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno K, Chalmers ZR, Pamarthy S et al (2021) Activated ALK cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer. Cancer Res 81:2157\u20132170","journal-title":"Cancer Res"},{"key":"11878_CR30","doi-asserted-by":"publisher","unstructured":"Luo J, Wang K, Yeh S et al (2019) LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling. Nat Commun 10. https:\/\/doi.org\/10.1038\/S41467-019-09784-9","DOI":"10.1038\/S41467-019-09784-9"},{"key":"11878_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/PROS.24448","volume":"83","author":"S Cheng","year":"2023","unstructured":"Cheng S, Yu X (2023) CTPC, a combined transcriptome data set of human prostate cancer cell lines. Prostate 83:158\u2013161. https:\/\/doi.org\/10.1002\/PROS.24448","journal-title":"Prostate"},{"key":"11878_CR32","doi-asserted-by":"publisher","first-page":"24809","DOI":"10.1074\/JBC.M113.468579","volume":"288","author":"S Su","year":"2013","unstructured":"Su S, Minges JT, Grossman G et al (2013) Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins. J Biol Chem 288:24809\u201324824. https:\/\/doi.org\/10.1074\/JBC.M113.468579","journal-title":"J Biol Chem"},{"key":"11878_CR33","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/PROS.21214","volume":"70","author":"T Suyama","year":"2010","unstructured":"Suyama T, Shiraishi T, Zeng Y et al (2010) Expression of cancer\/testis antigens in prostate cancer is associated with disease progression. Prostate 70:1778\u20131787. https:\/\/doi.org\/10.1002\/PROS.21214","journal-title":"Prostate"},{"key":"11878_CR34","doi-asserted-by":"publisher","unstructured":"Kagohara LT, Carleton NM, Takahashi S et al (2019) Cancer\/Testis Antigens Differentially Expressed in 2 Prostate Cancer: Potential New Biomarkers and Targets 3 for Immunotherapies 4. https:\/\/doi.org\/10.1101\/646869","DOI":"10.1101\/646869"},{"key":"11878_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1385\/IJGC:33:2-3:141","volume":"33","author":"DE Hansel","year":"2003","unstructured":"Hansel DE, House MG, Ashfaq R et al (2003) MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int J Gastrointest Cancer 33:141\u2013147. https:\/\/doi.org\/10.1385\/IJGC:33:2-3:141","journal-title":"Int J Gastrointest Cancer"},{"key":"11878_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","volume":"37","author":"JL Weon","year":"2015","unstructured":"Weon JL, Potts PR (2015) The MAGE protein family and cancer. Curr Opin Cell Biol 37:1\u20138. https:\/\/doi.org\/10.1016\/j.ceb.2015.08.002","journal-title":"Curr Opin Cell Biol"},{"key":"11878_CR37","doi-asserted-by":"publisher","unstructured":"Song Y, Hou Z, Zhu L et al (2025) Oxidative stress as a catalyst in prostate cancer progression: unraveling molecular mechanisms and exploring therapeutic interventions. Discover Oncol 16. https:\/\/doi.org\/10.1007\/S12672-025-02245-4","DOI":"10.1007\/S12672-025-02245-4"},{"key":"11878_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1152\/JAPPLPHYSIOL.00042.2016","volume":"121","author":"MJ Crilly","year":"2016","unstructured":"Crilly MJ, Tryon LD, Erlich AT, Hood DA (2016) The role of Nrf2 in skeletal muscle contractile and mitochondrial function. J Appl Physiol (1985) 121:730\u2013740. https:\/\/doi.org\/10.1152\/JAPPLPHYSIOL.00042.2016","journal-title":"J Appl Physiol (1985)"},{"key":"11878_CR39","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1038\/s41388-021-01899-y","volume":"40","author":"M Hagiwara","year":"2021","unstructured":"Hagiwara M, Fushimi A, Yamashita N et al (2021) MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene 40:4930\u20134940","journal-title":"Oncogene"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11878-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:35:44Z","timestamp":1777959344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11878"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11878-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"710"}}